Physician profile
Brendon L Bower
NPI 1972070316
$64,413.59
in general payments reported to CMS, 2019-2025
31 companies · $39K in 2025
The $39K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $500 · 2022: $1,477 · 2023: $3,487 · 2024: $20K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Travel and Lodging: $8,681 · Food and Beverage: $6,151 · Consulting Fee: $4,750 · Honoraria: $4,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,635.00 |
| Travel and Lodging | $8,680.76 |
| Food and Beverage | $6,150.84 |
| Consulting Fee | $4,750.00 |
| Honoraria | $4,220.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $35,842.60 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $17,286.72 | 2023-2025 | Voquezna, Voquezna Dual Pak, Voquezna Triple Pak |
| Qol Medical, LLC | $3,538.93 | 2024-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $1,090.26 | 2025 | Livdelzi |
| Ardelyx, INC. | $1,014.41 | 2022-2025 | Ibsrela |
| Abbvie INC. | $843.88 | 2022-2025 | |
| Novo Nordisk INC | $810.80 | 2024-2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $752.66 | 2022-2024 | Dupixent |
| Siemens Medical Solutions USA, INC. | $500.00 | 2021 | |
| Madrigal Pharmaceuticals | $348.37 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $320.92 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $305.15 | 2022-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $267.14 | 2023-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $241.03 | 2022-2025 | Entyvio, Eohilia |
| Amgen INC. | $127.63 | 2023-2025 | Repatha, Amjevita, Avsola |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $123.46 | 2025 | Cabenuva |
| Fresenius Kabi USA, LLC | $112.03 | 2023-2024 | Idacio |
| Celgene Corporation | $106.60 | 2022-2024 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $102.86 | 2025 | Austedo Xr |
| Daiichi Sankyo INC. | $83.22 | 2024-2025 | Injectafer |
| Neurocrine Biosciences, INC. | $82.68 | 2025 | |
| Sumitomo Pharma America, INC. | $82.60 | 2025 | Myfembree |
| Emd Serono, INC. | $80.31 | 2024 | |
| Sage Therapeutics, LLC | $79.73 | 2025 | |
| Exact Sciences Corporation | $78.95 | 2025 | Cologuard Collection Kit |
| Celltrion USA INC. | $58.50 | 2024-2025 | Vegzelma |
| Merck Sharp & Dohme LLC | $36.53 | 2022-2024 | Zinplava, Dificid |
| Ipsen Biopharmaceuticals, INC | $29.01 | 2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $26.35 | 2024 | |
| Pfizer INC. | $25.03 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $15.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brendon Bower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.